Smith & Nephew plc (LON:SN) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Smith & Nephew plc (LON:SN) have received an average recommendation of “Hold” from the nine analysts that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is GBX 1,242.50.

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada cut their target price on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a report on Thursday, August 6th. Jefferies Financial Group lowered their price target on shares of Smith & Nephew from GBX 1,500 to GBX 1,400 and set a “buy” rating for the company in a report on Thursday, November 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,250 price target on shares of Smith & Nephew in a research report on Tuesday, September 15th. Berenberg Bank cut their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. cut their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a report on Thursday, August 6th.

Smith & Nephew Trading Down 1.8%

SN stock opened at GBX 1,140.50 on Thursday. The stock has a fifty day moving average of GBX 1,060.26 and a 200 day moving average of GBX 1,151.46. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The company has a market capitalization of £12.50 billion, a PE ratio of 41.06, a price-to-earnings-growth ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.